In June 2025, the Centre Baclesse shone on the international stage, thanks in particular to the oral communications of Dr Audrey FAVEYRIAL, on the initial results of the OPTIMACURE study.
Presentation of the first results of the OPTIMACURE study
Sunday June 1: Dr FAVEYRIAL, oncologist at the Centre Baclesse, took part in theAmerican Society of Clinical Oncology's (ASCO ) annual cancer conference in Chicago, in a fast-paced 6-minute "rapid oral abstract session", in the Research on quality of healthcare and health services category.
Thursday June 26: Dr FAVEYRIAL travelled to Seattle to take part in the International Interdisciplinary Supportive Cancer Care Conference, The Multinational Association of Supportive Care in Cancer (MASCC).
Why this OPTIMACURE study?
From pioneering innovation to today's tool: from OPTIMA to Cureety®.
At the Centre Baclesse, innovation is at the heart of our daily work. More than ten years ago, our facility was already a forerunner, developing the OPTIMA (OPTImisation de la Médecine Ambulatoire) program in-house. This telephone platform, designed by our teams in 2012-2013, with initial financial support from the Roche laboratory, has revolutionized patient care in day hospitals. By calling patients 48 hours before they come in, we have been able to anticipate prescriptions, optimize resources and, above all, reduce waiting times for our patients.
After a decade of loyal service, it was time to adapt the tool to today's needs. We therefore made the transition to Cureety®, a modern remote monitoring solution now reimbursed by the French health insurance system. This transition took place between December 2023 and March 2025, enabling us to carry out the OPTIMACURE study.
More than just a replacement for a digital tool, the integration of remote monitoring in day hospital :
- Improves regular monitoring by the care team in charge of the patient,
- Reinforces the coordination of different healthcare professionals around the patient,
- Improves quality of life by preventing complications,
- Provides care as close to home as possible, optimizing travel time
The OPTIMACURE study
These digital innovations are interesting to deploy at the Centre, but we needed to measure their impact objectively. Hence this study...
- Objective: Evaluate the impact of a remote monitoring system on the management of patients undergoing chemotherapy.
- Method: Usually, preparing treatment sessions and monitoring side effects required numerous telephone calls from the treatment team. The OPTIMACURE study compared two groups of patients:
- 1 group receiving the usual follow-up,
- 1 other group also using the Cureety® remote monitoring application
- Results: The results are clear: use of the application has significantly reduced the number of outgoing calls to the day hospital to prepare chemotherapy sessions.
At the same time, there has been an increase in the number of calls from the care team concerning side effects. This increase suggests that theapplication enables toxicities to be better identified and managed more quickly, thus ensuring greater safety and more responsive care for patients.
